Verastem
VSTMVerastem is a commercial-stage biopharmaceutical company focused on developing and commercializing small molecule therapies for RAS/MAPK pathway-driven cancers.
Table of contents
Earnings
Next report
Aug 6, 2026 (In 1 week)Competitors
By market cap
By revenue growth
Profile
Verastem is a commercial-stage biopharmaceutical company focused on developing and commercializing small molecule therapies for RAS/MAPK pathway-driven cancers. The company's core value proposition lies in its precision targeting of signaling pathways that promote cancer cell survival and tumor growth, specifically through the inhibition of RAF, MEK, FAK, and KRAS. Their lead commercial product is the first FDA-approved treatment specifically for KRAS-mutated recurrent low-grade serous ovarian cancer.
Verastem holds a first-mover advantage in the KRAS-mutated LGSOC market with the first FDA-approved therapy for this specific indication.
Questions, answered.
- What is Verastem's market cap?
- Verastem (VSTM) has a market capitalization of $534.3M and trades on NASDAQ.
- Who are Verastem's competitors?
- Verastem's key competitors include Eli Lilly, AbbVie, Bristol Myers Squibb, and others. These companies compete in similar markets and product categories.
- Who does Verastem partner with?
- Verastem's notable partners include GenFleet Therapeutics, Chugai Pharmaceutical Co., Ltd., Pfizer Inc., and others.
- Where is Verastem headquartered?
- Verastem is headquartered in United States of America and employs approximately 73 people. It has been publicly traded since 2012.